Despite Medicare coverage, many cancer patients still do not receive testing that guides treatment options

While there has been a recent increase among Medicare recipients in genomic testing that helps match cancer patients to the most effective treatment for their tumor, many Medicare beneficiaries with cancer are still not receiving next-generation sequencing (NGS), according to a new analysis by Georgetown University researchers.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup